Sun Pharma’s weight loss drug to hit the market in 5 years
We plan to launch our experimental anti-obesity and type 2 diabetes drug in the next four to five years, Dilip Shanghvi, CEO of Sun Pharmaceutical, India’s largest pharmaceutical company by revenue, said on Friday.
Sun Pharmaceutical is among many Indian drugmakers looking to capture a slice of the growing weight loss drug market, which is expected to reach $150 billion worldwide by the end of this decade.
The experimental drug, called Utreglutide/GL0034, belongs to a class of drugs called GLP-1, which suppress appetite by mimicking gut hormones. The drug’s medical benefits are also set to go beyond type 2 diabetes and weight loss.
Sun Pharmaceuticals, which expects to conduct mid-phase studies of utareglutide this year, previously said the drug had shown significant weight loss and metabolic improvements in early-phase studies.
